📣 VC round data is live. Check it out!
- Public Comps
- enGene
enGene Valuation Multiples
Discover revenue and EBITDA valuation multiples for enGene and similar public comparables like Prothena Corp., TTY Biopharm, Forte Biosciences, Luzhu Biotech and more.
enGene Overview
About enGene
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Founded
2023
HQ

Employees
82
Website
Financials (FY)
EV
$330M
Valuation Multiples
Start free trialenGene Stock Performance
enGene has current market cap of $572M, and enterprise value of $330M.
Market Cap Evolution
enGene's stock price is $8.54.
enGene share price increased by 122.4% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $330M | $572M | 0.0% | — | -15.5% | 122.4% | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialenGene Valuation Multiples
enGene Financial Valuation Multiples
As of May 5, 2026, enGene has market cap of $572M and EV of $330M.
| LTM | Last FY | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified enGene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


enGene Competitors
enGene competitors include Prothena Corp., TTY Biopharm, Forte Biosciences, Luzhu Biotech, Boan Biotech, Tectonic Therapeutic, Boiron, Altimmune, Supriya Lifescience and Avalon Pharma.
Most enGene public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 29.1x | 7.7x | (1.5x) | — | |||
| 2.6x | 2.5x | 7.0x | — | |||
| — | — | (7.2x) | — | |||
| — | 17.4x | (27.0x) | (170.5x) | |||
| 4.4x | 4.3x | 26.0x | 42.2x | |||
| — | — | (4.3x) | — | |||
| 0.9x | — | 6.8x | — | |||
| 8516.7x | 12003.7x | (4.0x) | (3.2x) | |||
This data is available for Pro users. Sign up to see all enGene competitors and their valuation data. Start Free Trial | ||||||
enGene Funding History
Before going public, enGene raised $25M in total equity funding, across 2 rounds.
enGene Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout enGene
| When was enGene founded? | enGene was founded in 2023. |
| Where is enGene headquartered? | enGene is headquartered in Canada. |
| How many employees does enGene have? | As of today, enGene has over 82 employees. |
| Who is the CEO of enGene? | enGene's CEO is Ronald Harold Wilfred Cooper. |
| Is enGene publicly listed? | Yes, enGene is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of enGene? | enGene trades under S0N ticker. |
| When did enGene go public? | enGene went public in 2023. |
| Who are competitors of enGene? | enGene main competitors include Prothena Corp., TTY Biopharm, Forte Biosciences, Luzhu Biotech, Boan Biotech, Tectonic Therapeutic, Boiron, Altimmune, Supriya Lifescience, Avalon Pharma. |
| What is the current market cap of enGene? | enGene's current market cap is $572M. |
| Is enGene profitable? | No, enGene is not profitable. |
| How many companies enGene has acquired to date? | enGene hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies enGene has invested to date? | enGene hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to enGene
Lists including enGene
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.